Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Leerink Partners Initiates Coverage On I-MAB with Outperform Rating, Announces Price Target of $9

Author: Benzinga Newsdesk | October 03, 2025 06:55am
Leerink Partners analyst Daina Graybosch initiates coverage on I-MAB (NASDAQ:IMAB) with a Outperform rating and announces Price Target of $9.

Posted In: IMAB

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist